Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma (NCT05948475)

🧪 Interventions in This Study

• Tinengotinib 8 mg (DRUG)
• Tinengotinib 10 mg (DRUG)
• Physician's Choice (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (87 Sites)

Showing the first 25 of 87 sites.

• UCLA Medical Center — Santa Monica, California
• Stanford Cancer Center — Stanford, California
• The University of Kansas Cancer Center — Westwood, Los Angeles, California
• Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida
• The University of Chicago Hospitals — Chicago, Illinois
• UMass Memorial Medical Center — Worcester, Massachusetts
• University of Michigan — Ann Arbor, Michigan
• Henry Ford — Detroit, Michigan
• University of Minnesota- Masonic Cancer Center, M Health Fairview — Minneapolis, Minnesota
• Roswell Park Comprehensive Cancer Center — Buffalo, New York
• Messino Cancer Centers — Asheville, North Carolina
• University Hospitals Cleveland Medical Center — Cleveland, Ohio
• Tennessee Oncology- Nashville — Nashville, Tennessee
• Vanderbilt-Ingram Cancer Center — Nashville, Tennessee
• University of Texas Southwestern Medical Center — Dallas, Texas
• Texas Oncology-Sammons Cancer Center — Dallas, Texas
• The University of Texas MD Anderson Cancer Center — Houston, Texas
• University of Virginia Cancer Center — Charlottesville, Virginia
• Medical College of Wisconsin — Milwaukee, Wisconsin
• Ordensklinikum Linz GmbH — Linz,
• Landesklinikum Wiener Neustadt — Wiener Neustadt,
• Universitair Ziekenhuis Antwerpen — Antwerp,
• Universitair Ziekenhuis Gent — Ghent,
• Universitair Ziekenhuis Leuven — Leuven,
• Institut Sainte Catherine - Institut du Cancer Avignon Provence — Avignon,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Cholangiocarcinoma

• Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations — Phoenix, Arizona
• An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma — Yerevan,
• [18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma — Seattle, Washington
• Cell-Surface Plectin in the Diagnosis of Cholangiocarcinoma from ERCP-directed Biliary Samples — Charlottesville, Virginia
• Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid — St Louis, Missouri

Explore by condition: All Cholangiocarcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.